About Authors:
*C.P. Meher,  S.P.Sethy, B.Pochaiah
Department of pharmaceutical Bio-Chemistry,
Maheshwara college of Pharmacy, chitkul (V),
Isnapur “X” Road,  patancheru, Hyderabad.

“Enzyme are the catalyst of the living world ! protein in nature, and in action in specific ,rapid and accurate; huge in size but with small active centers; highly exploited for disease diagnosis in lab centers”[1] Enzyme promotes & control the conversion of the complex carbohydrates, fats & protein of our body into simple substances which the intestine can absorb & also the various reaction by which these simple substances are used in the body for building up new tissue  or producing energy. The enzyme are not broken down or changed in the process . they are as potent at the end of the reaction at the beginning & very small amounts can effect the conversion of large quantity of material . they are the true catalyst.[2] They are actively take part in every metabolic pathways that occur in our body. This review is concern with comparative study of the various enzyme related with various metabolic pathways as well as the drugs associated for inhibition to give respective pharmacological responses.

Career for Masters in pharmacy/ Bachelors of Pharmacy as Team Member - Process Development in Mylan

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline.


About Authors:
A.Tamil Selvan*, R.Suresh1, D.Benito Johnson2, R.Suresh Kumar3, R.Venkatanarayanan4, L.Sivakumar5
Department of Pharmacology
Teegala Ram Reddy College of Pharmacy, Meerpet, Hyderabad – 97
1-4RVS College of Pharmaceutical Sciences, Sulur, Coimbatore- 641402
5SKM Siddha and Ayurvedha Company (India) Limited, Erode - 638104.


In this study, polyherbal extract of Cycas circinalis, Nardostachys jatamansi and Artemisia absinthium ethanolic fraction was explored for its antidepressant property using Forced swim test (FST) and Tail suspension test (TST). Many of its individual constituents have been used for central nervous system (CNS) activities but no systematic work was carried on this combination. In this study its effect on depression was explored in rats. For this purpose the plants part were extracted by successive solvent extraction by Soxhylation. Ethanolic extract was chosen for the pharmacological evaluation, based upon the phytochemical and instrumental analysis. The ethanolic extract was subjected to FT-IR analysis for finding the possible number and nature of function groups present in it. Also the extract was analysed by HPLC for the number possible phytocompounds/phytoconstituents present, which may directly or indirectly involve in the brain neurochemical activity. Acute and Subacute toxicity study revealed the dose upto 2000mg/kg the extract had not toxic symptoms and no mortality. The therapeutic dose was found to be 200mg/kg and there was no toxic damage to liver and kidney observed in subacute toxicity study. The ethanolic extract of the polyherbal combination exhibited significant (P<0.001) antidepressant activity  as indicated by its ability to decrease swim stress and tail suspension induced immobility time in rats as compared with that standard Fluoxetine. As well as restoring biogenic amines to normal level that was altered by the swim stress and tail suspension test in whole rat brain assay by HPTLC method. The result indicates this polyherbal combination can be a potential candidate for .managing depression. However further studies are required to confirm the exact therapeutic efficacy.

Career opportunity as Quality Assurance Manager in Procter and Gabmle (P&G)

Procter & Gamble is the innovation leader in our industry. Virtually all the organic sales growth we’ve delivered in the past nine years has come from new brands and new or improved product innovation. We continually strengthen our innovation capability and pipeline by investing two times more, on average, than our major competitors.